DCP Capital, a private equity firm, agreed to acquire a 9% stake in Tonghua Dongbao Pharmaceuticals, a manufacturer of generic medicines for $283m. "We are excited to have DCP as our strategic investor. The cooperation between Dongbao Group, our controlling shareholder, and DCP is a win-win partnership. We look forward to working with DCP on various initiatives, such as operational improvements, M&A, and international development. Tonghua Dongbao will continue to focus on its core business in diabetes treatment, further strengthen the product pipeline, and create value for all our shareholders," Chunsheng Leng, Tonghua Dongbao Chairman and CEO.